Patent application number | Description | Published |
20100105643 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 04-29-2010 |
20100318063 | DUAL BARREL SYRINGE ASSEMBLY - A syringe system for dispensing or injecting one or more fluids is provided. The syringe system includes a hollow body that retains cartridge(s) and/or syringe(s) each containing a fluid, such as an injectable fluid e.g., a catalyst in one cartridge and a polymer in the other. Upon use for dispensing two fluids, the syringe system mixes the two fluids immediately prior to or concurrently with the dispensing or injecting of the fluids. The syringe system can also be configured to independently dispense a single fluid or immediately dispense multiple fluids sequentially. | 12-16-2010 |
20110082543 | Methods and Devices for Preventing or Delaying Posterior Capsule Opacification - Several methods for preventing, minimizing, or delaying the incidence of posterior capsule opacification are provided. A first method involves chemically activating the surface of an implantable ocular device, such as an intraocular lens or a capsular tension ring, by grafting a chemical moiety onto the surface of the device, covalently attaching a non-cytotoxic inhibitor compound to the chemical moiety to produce an inhibitor implantable ocular device, and implanting this inhibitor implantable ocular device into the capsular bag of an eye of a patient during extracapsular cataract surgery. Appropriate inhibitor compounds include RGD mimetics, RGD peptides, and flavonoids. A second method involves surface modifying the exterior surface of a capsular tension ring by covalently attaching a mitotic inhibitor, preferably a conjugate of methotrexate and a bovine serum albumin, and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. A third method involves surface modifying the exterior surface of a capsular tension ring by coating or grafting the exterior surface with a charged polyethylamine and implanting this inhibitor tension ring into the capsular bag of an eye of a patient during extracapsular cataract surgery. An implantable ocular device according to the invention, such as an intraocular lens or a capsular tension ring, contains a substrate with a chemical moiety grafted thereon and a non-cytotoxic inhibitor compound covalently bonded to the chemical moiety or contains a substrate modified with a mitotic inhibitor or charged polyethylamine. The inhibitor devices inhibits proliferation and migration of lens epithelial cells on the posterior capsule of the eye of the patient, thereby preventing, minimizing, or delaying the onset of posterior capsule opacification. | 04-07-2011 |
20110229452 | Ophthalmic Surgical Irrigating Solutions Containing Hyaluronidase - An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells. | 09-22-2011 |
20120134662 | VIEWFINDER - A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, attachment means connected to said base member for coupling the base member to an electronic device, an open-ended housing disposed on the base member, and a sighting grid disposed adjacent an open end of the open-ended housing and method for using same is provided. | 05-31-2012 |
20120189297 | Viewfinder - A viewfinder including a base member for removably mounting on an electronic device suitable for taking digital photographs, and an open-ended housing disposed substantially perpendicular to, and offset from the base member is disclosed. The housing includes a sighting grid disposed adjacent an open end of the open-ended housing. | 07-26-2012 |
20120301128 | Viewfinder - According to an aspect of the invention, a case or slide-on unit suitable for containing an electronic device is disclosed. The case or slide-on unit incorporates a viewfinder housing assembly that allows a user to view an image when taking a picture with the electronic device. The housing assembly includes a sighting grid that allows a user to orient an image within a field of view in order to properly capture the image | 11-29-2012 |
20120316143 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 12-13-2012 |
Patent application number | Description | Published |
20090192207 | Topical Formulations Comprising 1-N-Arylpyrazole Derivatives and Amitraz - The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs. | 07-30-2009 |
20130023490 | TOPICAL FORMULATIONS COMPRISING 1-N-ARYLPYRAZOLE DERIVATIVES AND AMITRAZ - The present invention provides for, inter alia, novel topical formulations comprising at least one 1-N-arypyrazole derivative and amitraz and to methods for treating, controlling, or preventing parasite infestations on mammals or birds The inventive formulations include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an IGR compound, an avermectin or milbemycin derivative, or a pyrethroid insecticides, and anthelmintics, such as benzimidazoles and imidazothiazoles. The inventive formulation provides a larger duration of parasite control at a faster rate of control. The inventive formula remains effective up to three months from the first application. Moreover, the inventive formulations prevent tick attachment to the animal, thereby providing protection against tick borne diseases. The ectoparasites which may be controlled, treated or prevented by the present invention includes ticks, fleas, mites, mange, lice, mosquitoes, flies and cattle grubs. | 01-24-2013 |
20130065846 | PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF - This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 03-14-2013 |
20160051519 | PARASITICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF - This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 02-25-2016 |
Patent application number | Description | Published |
20080312272 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): | 12-18-2008 |
20090163575 | SOLVENT SYSTEMS FOR POUR-ON FORMULATIONS FOR COMBATING PARASITES - This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep. | 06-25-2009 |
20100125089 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): | 05-20-2010 |
20100125097 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF - This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof. | 05-20-2010 |
20110028495 | THE USE OF 6-HALOGENO-[1,2,4]-TRIAZOLO-[1,5-a]-PYRIMIDINE COMPOUNDS FOR COMBATING PESTS IN AND ON ANIMALS - The present invention relates to the use of 6-halogeno-[1,2,4]-triazolo[1,5-a]-pyrimidine compounds of the general formula I | 02-03-2011 |
20120149750 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): | 06-14-2012 |
20120252667 | INSECTICIDAL 4-AMINO-THIENO[2,3-D]-PYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE - Insecticidal 4-Amino-thieno[2,3-d]-pyrimidine compounds and methods of their use to control pests that damage plants and crops and parasites that harm animals. | 10-04-2012 |
20130203692 | PARASITICIDAL ORAL VETERINARY COMPOSITIONS COMPRISING SYSTEMICALLY-ACTING ACTIVE AGENTS, METHODS AND USES THEREOF - This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof. | 08-08-2013 |
20130225516 | TOPICAL COMPOSITIONS COMPRISING FIPRONIL AND PERMETHRIN AND METHODS OF USE - The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of fipronil to its sulfone, and their uses in topical applications on animals and the environment. Useful formulations comprise from about 30% to about 55% (w/w) permethrin and about 2 to 15% (w/w) fipronil and a solvent system that comprises N-methylpyrrolidone and a glycol, glycol ether, glycol ester, fatty acid ester or neutral oil, wherein the N-methylpyrrolidone and glycol, glycol ether, glycol ester, fatty acid ester or neutral oil are present in a weight:weight ratio of from about 1:2.0 to about 1:3.5, glycol, glycol ether, glycol ester, fatty acid ester or neutral oil to n-methylpyrrolidone. These two actives when combined in the described amounts have been found to have unexpected enhanced repellent activity against stable fly. However, it is the formulations described herein that provide solvency and stability that maintain synergistic concentrations after application on an animal. | 08-29-2013 |
20130256170 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF - This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds alone or in combination with formamidine compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to the animal in need thereof. | 10-03-2013 |
20140080862 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): | 03-20-2014 |
Patent application number | Description | Published |
20120266399 | Device Having Dual Renewable Blades For Treating a Target Surface and Replaceable Cartridge Therefor - A device for treating a target surface, such as occurs when cleaning a window. The device has a squeegee blade or other member to apply pressure to the target surface. A sheet movably covers the blade, to present a fresh covering to the target surface with each use. The fresh surface provides for improved removal of the liquid from, or improved treatment of the liquid on, the target surface. Additionally a sheet may comprise a prewetted substrate to apply the liquid to the target surface. One or both of the sheets may be disposed in a cartridge insertable to and removable from the device. | 10-25-2012 |
20120266915 | Plural Zoned Substrate Usable for Treating a Target Surface - A device for treating a target surface, such as occurs when cleaning a window. The device has a substrate. The substrate has plural, alternating zones. One zone may apply a liquid to the target surface, while the immediately succeeding zone removes the liquid from the target surface. The following plural zones may be used to repeat this process. | 10-25-2012 |
20120266916 | Squeegee Having at Least One Renewable Blade Surface For Treating a Target Surface - A device for treating a target surface, such as occurs when cleaning a window. The device has plural squeegee blades joined by a head. The head has a slot therethrough. A sheet may be longitudinally move over one or more than one of the blades to renew its surface before, during or after use. Each squeegee blade may have a dedicated sheet. The sheet(s) may travel through the slot to originate from or be stored within the head. | 10-25-2012 |
20120266923 | Device Having a Renewable Blade Surface For Treating a Target Surface - A device for treating a target surface, such as occurs when cleaning a window. The device has a squeegee blade or other member to apply pressure to the target surface. A sheet movably covers the blade, to present a fresh covering to the target surface with each use. The fresh surface provides for improved removal of the liquid from, or improved treatment of the liquid on, the target surface. Additionally or alternatively, the sheet may comprise a prewetted substrate to apply the liquid to the target surface. | 10-25-2012 |
Patent application number | Description | Published |
20120077810 | Inhibitors Of AKT Activity - The instant invention provides for substituted fused pyrimidine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 03-29-2012 |
20120083483 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 04-05-2012 |
20140199263 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 07-17-2014 |
20140199264 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y | 07-17-2014 |
20140213571 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 07-31-2014 |
20140371138 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 12-18-2014 |
20150246902 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 09-03-2015 |